Organisation
Medical Oncology
Current researchers
21 - 22 of 22 results
- Manon Vounckx (Member)
- Amy de Haar-Holleman (Member)
Publications
1 - 10 of 280
- What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors?(2017)
Authors: Gaëlle Douchet, Sandrine Aspeslagh
Pages: 485-493 - Rationale for anti-OX40 cancer immunotherapy(2016)
Authors: Sandrine Aspeslagh, Sophie Postel-Vinay, Sylvie Rusakiewicz, Jean-Charles Soria, Laurence Zitvogel, Aurélien Marabelle
Pages: 50-66 - The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.(2008)
Authors: Ahmad Awada, Fatima Cardoso, Christel Fontaine, Luc Dirix, Jacques De Grève, Christos Sotiriou, J Steinseifer, C Wouters, C Tanaka, U Zoellner, et al.
Pages: 84-91 - Dendritic cell therapy for oncology roundtable conference.
Authors: Sandra Tuyaerts
- Wilms' Tumor Gene 1 (WT1) - loaded Dendritic Cell Immunotherapy in Patients with Uterine Tumors: A Phase I/II Clinical Trial
Authors: An Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, Tina Verschuere, Philippe Moerman, Zwi N Berneman, Ignace Vergote, Frederic Amant, Stefaan W Van Gool
Pages: 5495-5500 - Pleuropericardial effusion in CLL patients treated with ibrutinib: a causal relationship?
Authors: An-Sofie Vander Mijnsbrugge, Vincent Maertens, Daphne Wijsmans
Pages: 132-137 - Understanding genetic determinants of resistance to immune checkpoint blockers(2020)
Authors: Sandrine Aspeslagh, Roman M Chabanon, Stéphane Champiat, Sophie Postel-Vinay
Pages: 123-139 - Pathologische beoordeling van het resectieapparaat bij rectumkanker(2010)Volume: 4
Authors: Anne Hoorens, A. Jouret-Mourin, C. Sempoux, C. Cuvelier, N. Nagy, G. De Hertogh, K Geboes, Pieter Demetter
Pages: 135-145Number of pages: 10 - Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise(2020)
Authors: Daphné Morel, Daniel Jeffery, Sandrine Aspeslagh, Geneviève Almouzni, Sophie Postel-Vinay
Pages: 91-107 - Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma(2021)
Authors: Amélie Deleporte, Marc Van den Eynde, Frédéric Forget, Stéphane Holbrechts, Thierry Delaunoit, Ghislain Houbiers, Hassan R Kalantari, Stéphanie Laurent, Erik Vanderstraeten, Marc De Man, et al.
Pages: 4366-4374